CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
改善基于 piggyBac 转座子的 CD19 CAR-T 细胞制备与特性的新型无外源、无血清培养条件
英文原题：Novel xeno-free and serum-free culturing condition to improve piggyBac transposon-based CD19 chimeric antigen receptor T-cell production and characteristics.
查看英文原题
Novel xeno-free and serum-free culturing condition to improve piggyBac transposon-based CD19 chimeric antigen receptor T-cell production and characteristics.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们的研究支持使用无异种血清替代物作为 piggyBac-based CAR-T 细胞扩增的血清补充替代来源。
研究思路结论见上方概要
背景
嵌合抗原受体（CAR）T细胞是治疗复发/难治性血液系统恶性肿瘤的一种新型疗法。CAR-T 细胞的特征与临床疗效和毒性相关。培养过程中使用的血清补充剂类型会影响病毒载体CAR-T 细胞的免疫表型和功能。本研究探讨血清补充剂对非病毒piggyBac转座子CAR-T 细胞生产的影响。
方法
PiggyBac CD19 CAR-T 细胞在含有胎牛血清、人AB血清或无异种血清替代物的培养条件下扩增。我们评估了不同血清补充物对细胞扩增、转导效率、免疫表型和抗肿瘤活性的影响。
结果
无外源血清替代物与传统血清补充剂相比，展现出相似的CAR表面表达、细胞扩增及短期抗肿瘤活性。然而，使用无外源血清替代物培养的CAR-T 细胞显示出增加的初始/干细胞记忆群体，并且在长期共培养以及肿瘤再挑战实验中表现出更好的T细胞扩增能力。
展开英文摘要原文
METHODS
PiggyBac CD19 CAR T cells were expanded in cultured conditions containing fetal bovine serum, human AB serum or xeno-free serum replacement. We evaluated the effect of different serum supplements on cell expansion, transduction efficiency, immunophenotypes and antitumor activity.
RESULTS
Xeno-free serum replacement exhibited comparable CAR surface expression, cell expansion and short-term antitumor activity compared with conventional serum supplements. However, CAR T cells cultivated with xeno-free serum replacement exhibited an increased na ve/stem cell memory population and better T-cell expansion after long-term co-culture as well as during the tumor rechallenge assay.
CONCLUSIONS
Our study supports the usage of xeno-free serum replacement as an alternative source of serum supplements for piggyBac-based CAR T-cell expansion.
论文信息
- 作者
- Sanyanusin M、Tudsamran S、Thaiwong R、Tawinwung S、Nishio N、Takahashi Y、Hirankarn N、Suppipat K
- 第一作者单位
- Medical Microbiology, Interdisciplinary and International Program, Graduate School, Chulalongkorn University, Bangkok, Thailand.Thailand
- 通讯作者单位
- Cellular Immunotherapy Research Unit, Chulalongkorn University, Bangkok, Thailand; Chulalongkorn Comprehensive Cancer Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Department of Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Electronic address: Koramit.S@chula.ac.th.Thailand
- 文献类型
- 非美国政府资助研究
- 期刊
- Cytotherapy2023 Apr
- 原文标识
- PubMed 36517366 · DOI 10.1016/j.jcyt.2022.11.009